EWG Elevate’s Vertex Pharmaceuticals VRTX Stock Holding History

EWG Elevate’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-369	Closed	-$107K	–	771
2022 Q4	$107K	Buy	+369	New	+$112K	0.05%	115

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EWG Elevate's VRTX Position: Q1 2023 in Review

EWG Elevate sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 369 shares — an estimated $107K sold.

EWG Elevate first reported a position in VRTX in Q4 2022 and held it in 1 quarter. The position peaked at $107K in Q4 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

EWG Elevate reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EWG Elevate sold 369 Vertex Pharmaceuticals shares in Q1 2023, an estimated $107K.
EWG Elevate first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 1 quarter.
EWG Elevate's Vertex Pharmaceuticals position peaked at $107K in Q4 2022.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on EWG Elevate's 13F filing for Q1 2023, filed 13 Apr 2023.